SecBot SecBot
SECBOTREPLAY Home › Report › AZN

AZN · AstraZeneca announced positive Phase III SAFFRON trial results showing…

ASTRAZENECA PLC · 6-K filed Aug 17, 2026 at 07:03 ET

At the news

BULLISHIMPACT 7/10

6-K filed Aug 17, 2026 at 07:03 ET

AstraZeneca announced positive Phase III SAFFRON trial results showing Tagrisso plus Orpathys significantly improved progression-free survival (PFS) and overall survival (OS) vs chemotherapy in EGFR-mutated NSCLC patients with MET-driven resistance after Tagrisso progression. This is the first global Phase III to show both PFS and OS benefit in this setting, supporting global regulatory submissions and reinforcing Tagrisso's backbone role in EGFRm lung cancer.

  • SAFFRON Phase III trial met dual primary endpoint of PFS and key secondary endpoint of OS with statistical significance and clinical meaningfulness vs doublet platinum-based chemotherapy.
  • Trial enrolled 338 patients across 230 centers in 29 countries; patients had EGFRm NSCLC with high MET overexpression/amplification after progression on Tagrisso.
  • Safety profile consistent with known profiles of each medicine; no new safety findings.
  • Data to be presented at forthcoming medical meeting and shared with global regulatory authorities.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access